Top Biotech Companies in Singapore (91)
Established in 2001, Avalere Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Our team of 1,500+ experts combine their knowledge and expertise across our core disciplines—Consulting; Medical; Policy; Value, Evidence, and Access; Marketing; and Digital Experience Technology—to create the connections that make better health happen. We partner with our clients to navigate the...
Avalere Health's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Revenue expanded in consecutive years, with double‑digit growth in 2023 followed by continued albeit slower growth in 2024. Trade coverage frames 2024 as a cooling market overall, suggesting the company’s trajectory reflects resilience amid a softer cycle.
Strong Market Position & Advantage: Industry rankings place the firm consistently in the MM+M Agency 100 top 20 in 2024–2025. External awards and frequent policy visibility reinforce stature in core North American healthcare‑agency and U.S. policy/access segments.
Future-Ready Strategy: Leadership additions, a unifying rebrand, and integration of advisory, medical, access, and marketing indicate a connected commercialization model. New offerings, AI/data‑driven tools, partnerships, and the “Every Patient Possible” mission signal preparation for evolving client needs.
Analytical scientists and clinical researchers worldwide rely on Agilent to help fulfill their most complex laboratory demands. Our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. Whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or...
Agilent Technologies's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry and company materials consistently place Agilent among the top global players in analytical instrumentation—especially in chromatography and mass spectrometry—and as a frequent short‑list vendor for regulated and R&D labs. Recognition such as Instrument Business Outlook’s “Company of the Year” supports this standing.
Diversified Revenue Streams: The portfolio spans instruments, software/informatics, consumables, and services (Agilent CrossLab), with end‑to‑end workflows and specialty CDMO contributions providing multiple revenue levers. This breadth increases switching costs and drives recurring revenue that helps balance capital‑equipment cycles.
Resilient & Sustainable Growth: After a FY2024 decline, revenue returned to growth in FY2025 and continued in Q1 FY2026, with guidance pointing to mid‑single‑digit core growth and margin expansion. CrossLab’s steady growth and an instrument replacement cycle are cited as continuing supports.
As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster. Abcam partners with life science organizations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven...
Founded in 2019, Virtue Diagnostics is an in vitro diagnostic provider committed to platform innovation in emerging markets. We have built a management team with decades of experience in the in vitro diagnostic industry and a global vision, coupled with robust R&D, operation and commercialization capabilities. We set up our industrialization bases in China, Brazil and Indonesia, and R&D centers...
Biomed Global is a leading total solution provider in the biomedical and life sciences industry, operating across Southeast Asia. The company provides a holistic range of innovative medical solutions and cutting-edge biomedical technologies spanning research, development, and clinical applications. Its mission is to advance healthcare standards and facilitate medical breakthroughs by bringing together leading-edge medical solutions and expert support to...
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions....
Indegene's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst assessments place the company in leadership cohorts for life sciences commercial AI/analytics and digital services for commercial operations, indicating defensible positioning in its specialization. The company is also described as a best-fit provider for digital commercialization, omnichannel activation, content operations at scale, and AI-driven commercial analytics, reinforcing category leadership within that lane.
Strong Revenue Growth: Revenue shows clear acceleration into FY26, including a strong year-over-year increase in the latest reported quarter and a positive exit rate from prior quarters as deal wins converted. Full-year FY25 results also show year-over-year growth alongside continued profitability, supporting an upward growth trajectory.
Product Line Growth: Capability expansion is evidenced by recent acquisitions intended to deepen data-driven omnichannel, media offerings, and consulting/transformation coverage, broadening the commercialization toolkit. Ongoing scaling post-IPO is also framed as broadening capabilities beyond prior scope within its core focus areas.
Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing. We help our customers #SimplifyProgress from drug discovery to manufacturing so that more people can have access to better medicine. With this, we are #PartOfTheSolution in the fight against diseases worldwide. With innovative laboratory instruments and consumables, the our Lab Products & Services division focuses on laboratories performing...
Sartorius's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent market analyses repeatedly characterize Sartorius as a top‑tier leader in single‑use bioprocessing, particularly in single‑use bioreactors, bags/assemblies, and integrated upstream platforms. Broad scale from bench to 2,000‑L, a large installed base, and continued capacity expansions reinforce this position.
Strong Revenue Growth: Company disclosures indicate sales grew 7.6% in constant currencies in 2025 to about €3.54 billion, with Q1 2026 up 7.5% and full‑year 2026 guidance of 5–9% growth. Order intake recovery from late 2024 and momentum in Bioprocess Solutions underpin this trend.
Profitability: Underlying EBITDA increased faster than sales in 2025, with margin near 30%, and management expects robust margins into 2026. Improving cash generation and recurring consumables contribute to sustained profitability.
Suzano S.A. is a global leader in eucalyptus pulp production and one of the largest producers of paper and packaging in Latin America. Operating as a bioeconomy company, it develops sustainable and innovative products from renewable raw materials, reaching over two billion people in more than 100 countries globally. Its extensive portfolio includes pulp, paperboard, and tissue paper, driven by...
Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. Learn...
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with...
Roche's Top Stability & Growth Strengths
Strong Market Position & Advantage: Roche is the global leader in in‑vitro diagnostics and remains a top‑tier biopharma with a significant oncology footprint. The dual Pharmaceuticals–Diagnostics model is a strategic differentiator at scale.
Strong Revenue Growth: Group sales rose 7% at constant exchange rates in 2025 and 6% at CER in Q1 2026, with both divisions contributing. Guidance for 2026 indicates continued mid–single‑digit CER growth.
Profitability: Profitability improved in 2025 alongside sales, with higher IFRS net income and core EPS growth. Management pointed to capacity to keep investing while rewarding shareholders.
Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health...
Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery
For over 35 years, IDT has been enabling genomics laboratories with an oligonucleotide manufacturing process unlike anyone else in the industry, with the most advanced synthesis, modification, purification, and quality control capabilities available. Through our founder's dedication to innovation, the highest standards of quality, and deep genomics expertise, IDT has evolved from a leading oligo manufacturer to a genomics solutions provider supporting areas such...
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.
Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.
Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.
Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its AlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Alluminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug...
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and...
Catalent, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyses consistently place Catalent among the top global CDMOs, with meaningful presence in outsourced finished‑dose approvals and a broad end‑to‑end network. Its scale across oral, sterile, biologics, and cell & gene therapy supports late‑stage and commercial programs globally.
Investor Backing & Capital Strength: Novo Holdings’ completed acquisition provides deep‑capital sponsorship and strategic validation, with U.S./EU clearance reinforcing the platform’s importance. Related transactions around sterile sites highlight the strategic value of capabilities aligned to high‑demand medicines.
Future-Ready Strategy: Private ownership and a refreshed operating model aim to focus investment on biologics, cell & gene therapy, and clinical supply. GLP‑1–linked demand signals and capacity plans into the coming years indicate preparedness for sustained growth.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to...
Amgen's Top Stability & Growth Strengths
Strong Revenue Growth: 2025 results show total revenues up 10% to $36.8 billion and guidance for 2026 at $37.0–$38.4 billion signals continued top‑line expansion.
Diversified Revenue Streams: Company updates indicate a broad base with roughly 40 marketed products and 14 blockbusters in 2024, and in 2025 eighteen products reached record sales with notable growth from Repatha, TEZSPIRE, EVENITY, BLINCYTO, and rare‑disease brands.
Strong Market Position & Advantage: Evidence suggests Amgen is widely regarded as a leader among large‑cap biotechs with significant scale and an expanded rare‑disease footprint following the Horizon acquisition.
MMR Consulting Inc. and its dedicated team of experienced consultants are committed to delivering high quality, robust solutions for the Pharmaceutical and Biotechnology industries. Our expertise includes Engineering (Process, Automation, Facilities), Capital Project Management of large/complex projects and programs, Commissioning Qualification Validation, and GMP Compliance services.
Biomatch specializes in connecting top talent with leading companies in the life sciences sector, including pharmaceuticals, biotechnology, and medical technology. They offer tailored recruitment solutions, conduct candidate assessments, and aim to find the right job match for candidates and experts for companies.
Twenty years ago, we pioneered the world's first clear aligners. Since then, we have continuously innovated with new products and technologies that are revolutionizing treatments for doctors and their patients. Invisalign clear aligners and the iTero Intraoral scanner help dental professionals achieve the clinical results they expect and deliver effective, advanced dental options to their patients. Helping change millions of lives,...
Align Technology's Top Stability & Growth Strengths
Strong Market Position & Advantage: Invisalign is broadly viewed as the clear leader in doctor‑directed clear aligners, reinforced by a large trained‑doctor base and an integrated digital workflow. Record Q4/FY 2025 volumes and revenue, alongside industry characterization as the market leader, support advantage durability.
Market Expansion: International regions (EMEA, Latin America, APAC) are cited as driving year‑over‑year volume growth, with contributions from teen/kids and adult segments and growing DSO/OSO channels. Continued gains outside North America align with guidance for additional growth into 2026.
Innovation-Driven Growth: An integrated platform spanning Invisalign, iTero scanners, and exocad software underpins a closed‑loop workflow that encourages adoption. Ongoing iTero Lumina upgrades and plans for directly 3D‑printed retainers/attachments in 2026 indicate a pipeline that can sustain future growth.
